Transforming growth factor-β and breast cancer: Tumor promoting effects of transforming growth factor-β by Dumont, Nancy & Arteaga, Carlos L
Review
Transforming growth factor-b b and breast cancer
Tumor promoting effects of transforming growth factor-b b
Nancy Dumont and Carlos L Arteaga
Vanderbilt University School of Medicine and Vanderbilt-Ingram Cancer Center, Nashville,
Tennessee, USA
Abstract
The transforming growth factor (TGF)-bs are potent growth inhibitors of normal epithelial
cells. In established tumor cell systems, however, the preponderant experimental evidence
suggests that TGF-bs can foster tumor–host interactions that indirectly support the viability
and/or progression of cancer cells. The timing of this ‘TGF-b switch’ during the progressive
transformation of epithelial cells is not clear. More recent evidence also suggests that
autocrine TGF-b signaling is operative in some tumor cells, and can also contribute to tumor
invasiveness and metastases independent of an effect on nontumor cells. The dissociation of
antiproliferative and matrix associated effects of autocrine TGF-b signaling at a
transcriptional level provides for a mechanism(s) by which cancer cells can selectively use
this signaling pathway for tumor progression. Data in support of the cellular and molecular
mechanisms by which TGF-b signaling can accelerate the natural history of tumors will be
reviewed in this section.
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CTL = cytotoxic T lymphocyte; EMT = epithelial-to-mesenchymal transition; JNK = c-Jun N-terminal kinase; MMP = matrix metalloproteases; 
PAI-1 = plasminogen activator inhibitor; PTHrP = parathyroid hormone-related protein; TbRI = TGF-b receptor type I; TbRII = TGF-b receptor type II;
TGF-b = transforming growth factor-b.
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Introduction
Although the transforming growth factor (TGF)-bs can be
tumor suppressive [1], there is increasing evidence that
TGF-b secretion by tumor cells and/or stromal cells within
the peritumoral microenvironment can contribute to tumor
maintenance and progression. How, then, can TGF-bs be
both tumor suppressive and tumor promoting? This appar-
ent paradox is reconciled by a study showing that, in a
mouse skin model of chemical carcinogenesis, targeted
expression of TGF-b1 in suprabasal keratinocytes appears
to have dual effects. It suppresses the formation of benign
skin tumors, but once tumors develop, it enhances their
progression to a highly invasive spindle cell phenotype
[2••]. These results suggest that the effects of TGF-b1 are
biphasic: TGF-b1 acts early as a tumor suppressor, proba-
bly by inhibiting the proliferation of nontransformed cells,
and it acts later as a tumor promoter by eliciting an epithe-
lial-to-mesenchymal transition (EMT). Additional experi-
ments have suggested that upregulation of TGF-b3 in the
spindle carcinomas was responsible for maintenance of
this invasive phenotype [2••]. This is consistent with
TGF-b3 expression at sites in mouse embryos where
epithelial–mesenchymal interactions are important, like the
lung and palatal shelves [3,4], and also the abnormal lung
development and cleft palate observed in TGF-b3 null
mice [5]. Also consistent with an early tumor suppressive
effect is the recent observation that tgf-b1–/– mice develop
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colonic adenomas and cancers [6•]. The existence of dual
effects for TGF-bs in tumor progression follows the obser-
vation that TGF-b-induced growth inhibitory responses
and extracellular matrix responses may represent distinct
processes in certain cell types. For example, overexpres-
sion of the antagonistic Smad, Smad7, in pancreatic carci-
noma cell lines not only suppresses TGF-b1-mediated
growth inhibition, but enhances the ability of TGF-b1t o
induce matrix associated transcriptional responses [7•].
The progression of epithelial tumors to an invasive
metastatic state is often associated with EMT, downregu-
lation of cellular adhesion molecules, elevated expression
of metalloproteases, and increased motility and angiogen-
esis, all of which can be modulated by TGF-bs. It is there-
fore not surprising that the TGF-bs can also promote
tumorigenesis by modulating these critical processes. In
support of this view, elevated levels of TGF-b are often
observed in advanced carcinomas, and have been corre-
lated with disease progression in several studies [8–13].
This suggests that secreting higher levels of TGF-b may
provide an advantage to tumor cells. Both autocrine and
paracrine signaling may be involved in conferring this
selective advantage. While mutations in various compo-
nents of the TGF-b signaling pathway have been observed
in some carcinomas, particularly colorectal cancers
[14,15], an intact TGF-b signaling pathway is often
retained in other malignancies as some tumors can exhibit
increased invasiveness in response to exogenous TGF-b
[16,17•,18,19,20•,21]. Moreover, in a recent study of a
large cohort of human breast tumors, loss or low levels of
the type II TGF-b receptor (TbRII) correlated with high
tumor grade, but 60% of in situ and invasive breast carci-
nomas retained robust levels of TbRII expression by
immunohistochemistry [22]. Finally, although Smad4 is fre-
quently inactivated in pancreatic cancers [23,24], the
Smad genes, which encode proteins that transduce
TGF-b signals, are rarely mutated in most human carcino-
mas [25–30]. This suggests that after cells lose their sen-
sitivity to TGF-b growth inhibition, autocrine TGF-b
signaling may potentially promote tumor progression. In
addition, TGF-bs produced in excess by tumor cells may
act in a paracrine fashion on the peritumoral stroma, tumor
neovessels, or the immune system, indirectly fostering
tumor progression.
Autocrine effects
Epithelial-to-mesenchymal transition
Similar to keratinocytes [2••], TGF-b1 can also induce a
rapid and reversible EMT in melanoma cells [31], and in
both nontumor [32] and Ha-Ras transformed [17•]
mammary epithelial cells in vitro. In Ha-Ras mammary
tumors, EMT appears to be initiated by TGF-b produced
by peritumoral host cells and later maintained by autocrine
TGF-b1 as the converted tumor cells themselves begin to
secrete TGF-b1. The Ha-Ras tumor cells obtained after
EMT in vitro or in vivo display loss of epithelial polarity,
downregulation of E-cadherin, disruption of cell–cell adhe-
sion, and invasive properties in several in vitro assays
[17•]. Supporting the importance of autocrine TGF-b for
the tumorigenesis of Ha-Ras mammary cells, introduction
of dominant negative TbRII into these cells retarded tumor
formation and prevented EMT in vivo; moreover, introduc-
tion of the same construct into highly invasive murine
colon carcinoma cells reconstituted an epithelial pheno-
type in vitro, and inhibited both tumor outgrowth and the
establishment of metastases [20•]. In colon cancer cells of
low invasive potential and with naturally occurring muta-
tions in the TbRII gene, re-expression of TbRII function
restored tumor cell invasiveness [20•]. In another study,
expression of dominant negative TbRII in clones derived
from a metastatic squamous carcinoma cell line prevented
their spontaneous progression to a spindle phenotype in
vivo [21]. Furthermore, approximately 90% of colon
cancers with microsatellite instability have inactivating
mutations of TbRII [33], and this instability is significantly
correlated with longer patient survival [34], suggesting
that complete loss of TbRII in carcinomas may limit sys-
temic metastases. Taken together, these results suggest
that EMT, local tumor growth, and metastatic progression
can be sustained by autocrine TGF-b signaling.
When tumors are grown in nude mice, TGF-bs made by
host cells can induce responses in tumor cells with intact
TGF-b signaling, with the net effect of these tumor–host
interactions being deleterious to the host. For example,
MDA-231 human breast tumor cells secrete parathyroid
hormone-related protein (PTHrP) in response to exoge-
nous TGF-b1, metastasize to bone when injected into
nude mice, and induce osteolysis and hypercalcemia,
resulting in host death. Transfection of these cells with
dominant negative TbRII blocks TGF-b1-mediated stimula-
tion of PTHrP production. Mice injected with these cells
exhibited less osteolysis, higher body weight, lower serum
calcium and PTHrP levels, and longer survival than mice
injected with control MDA-231 cells [35•]. On the con-
trary, accelerated osteolysis and reduced host survival
were observed when mice where injected with tumor cells
transfected with a constitutively active TbRI, suggesting a
possible role for TGF-b-mediated responses in the patho-
genesis of some adverse paraneoplastic syndromes.
Several recent studies have contributed to our understand-
ing of the biochemical mechanisms by which transformed
cells can lose autocrine growth inhibition but retain TGF-b-
mediated responses that contribute to tumor progression.
For example, oncogenic activation of the Ras pathway,
acting via MAP kinases, causes phosphorylation of Smad2
and Smad3 at specific Erk consensus sites in the linker
region between their DNA binding and transcriptional
activation domains. This results in loss of nuclear accumu-
lation of Smad2/3 and silencing of TGF-b-mediatedhttp://breast-cancer-research.com/content/2/2/125
antiproliferative responses [36••]. In nontransformed
mammary cells, introduction of mutant Ras not only blocks
growth inhibition by TGF-b, but also subverts this pathway
into one that can stimulate epithelial-to-mesenchymal
transdifferentiation [17•,20•]. In MDCK epithelial cells,
transfection of the missense mutations Smad2.D450E
and Smad2.P445H, reported in primary colorectal and
lung carcinomas, does not abolish TGF-b-mediated growth
arrest. Instead, it increases both basal and TGF-b stimu-
lated invasiveness, neither of which is prevented by overex-
pression of the inhibitory Smad7 [37•]. This suggests the
existence of Smad ‘gain-of-function’ mutations that
enhance malignant progression by mechanisms indepen-
dent of TbRI and Smad phosphorylation. Another study has
shown that Smad7 mRNA levels are increased in human
pancreatic cancers compared with normal pancreas [7•].
Stable transfection of COLO-357 human pancreatic
cancer cells with a Smad7 expression vector results in loss
of TGF-b1-mediated growth inhibition and p21/Cip1 pro-
moter activity. However, TGF-b1-induced plasminogen
activator inhibitor-1 (PAI-1) promoter activity is maintained
and, more importantly, basal PAI-1 promoter activity, PAI-1
mRNA levels, anchorage independent colony growth, and
tumorigenicity in nude mice, are all increased in the Smad7
transfected clones [7•]. This result suggests another poten-
tial mechanism, the overexpression of Smad7, for the seg-
regation between antiproliferative and matrix associated
TGF-b responses. In addition, overexpression of Smad4 in
colon carcinoma cells does not reconstitute TGF-b-medi-
ated antiproliferative responses [38•,39], but inhibits cell
adhesion and spreading, reduces the levels of urokinase
plasminogen activator and PAI-1, and prolongs tumor
latency [39], suggesting an additional function for Smad4
in restraining genes involved in peritumor proteolysis and
invasion. This is further supported by reports of homozy-
gous deletion of TbRI or homozygous missense mutations
of TbRII [40,41], each coexisting with deletions of Smad4
in individual tumors. The coexistence of these mutations in
the same tumors would not be expected if the function of
these two gene products (TbRII and Smad4 or TbRI and
Smad4) was limited to a single common signal transduc-
tion pathway. Taken together, these studies suggest, first,
that the threshold for loss of TGF-b antimitogenic effects is
lower than that required to lose responses associated with
cell adhesion, invasion, and metastases; second, that not
one but multiple biochemical mechanisms can contribute
to the enhancement or unmasking of the tumor promoting
effects of autocrine TGF-b; and, third, that some of these
mechanisms may be independent of Smad function or TbRI
phosphorylation. The identification of Smad dependent and
independent genes causally involved in these TGF-b-medi-
ated tumor promoting effects requires further research. Of
note, Hocevar et al [42•] recently reported c-Jun N-termi-
nal kinase (JNK) dependent TGF-b-induced fibronectin
expression in cell lines lacking the Smad4 gene or protein
expression.
Increased motility
TGF-b can stimulate the motility of many cell types in vitro
[43–45], therefore suggesting that TGF-b production in
vivo may enhance migration of tumor cells and metastatic
potential. Indeed, cyclosporine treatment of lung adeno-
carcinoma cells results in increased cell motility and
anchorage independent growth in vitro, as well as
increased metastases in vivo, all of which can be blocked
with neutralizing TGF-b1 antibodies [46]. These results
suggest that in vivo tumor progression by cyclosporine is
dependent on autocrine TGF-b1. In prostate cancer cells,
TGF-b1 stimulates motility without affecting cell prolifera-
tion, suggesting that the effects on motility and prolifera-
tion may occur via different biochemical pathways [43].
Whether blockade of the Smad pathway, critical for
TGF-b-mediated antimitogenic effects [47,48], is also
critical for the effects of TGF-bs on cell motility is not
clear. Some evidence suggests that the latter may follow
alternative signaling pathways, perhaps in cooperation
with activated oncogenes. Atfi et al [49] reported
recently that inactivating components of the JNK
pathway, which regulates AP-1 activity via c-Jun, inhibits
TGF-b-mediated induction of 3TP-Lux, a reporter con-
struct that contains Smad and AP-1 binding elements.
Dominant negative mutants of RhoA, Rac1, and Cdc42,
GTPases that mediate cell shape, cytoskeletal organiza-
tion, and motility, abolish TGF-b-mediated transcription
of AP-1 [49,50], suggesting that the Rho family of
GTPases and the JNK pathway are essential compo-
nents of TGF-b signaling responses. TGF-b1 can also
upregulate integrin linked kinase [31], a protein associ-
ated with fibronectin production and increased cell motil-
ity. In another study, TGF-b1 treatment of NMuMG
mouse mammary epithelial cells increased the expres-
sion of N-cadherin [51], which has been shown to
increase motility of squamous cancer cells [52].
Paracrine effects
Induction of metalloproteases
Matrix metalloproteases (MMPs) play a critical role in the
proteolytic degradation of basement membrane that is
required for tumor invasion [53]. The expression of several
MMPs, including MMP-2 [54] and MMP-9 [18,31,55], can
be induced by TGF-b. Moreover, TGF-b1 has been shown
to selectively induce MMP-9 activity in a subset of
metastatic but not primary mouse prostate tumors, imply-
ing that this TGF-b1-induced response may be an impor-
tant selection step in tumor progression [18]. There is also
evidence that TGF-b increases MT-MMP-1 and MMP-9
expression in metastatic melanoma [31]. Although MMPs
are listed separately, recent data implicate them strongly
in the process of tumor-induced neovascularization [56],
thereby suggesting that their upregulation might be an
integral component of the TGF-b-mediated angiogenic
processes discussed next.Tumor angiogenesis
It is generally accepted that solid tumors require an ade-
quate blood supply in order to grow beyond a few milli-
meters in size. TGF-bs, particularly TGF-b1, have been
shown to regulate new blood vessel formation both in vitro
and in vivo by a combination of responses that include
increased production and facilitation of vascular endothe-
lial growth factor, facilitation of basic fibroblast growth
factor mediated capillary sprouting, inhibition of endothe-
lial cell migration, and increased production of extracellular
matrix, among others (reviewed in [57]). In most cells,
TbRI/ALK-5 is the signaling receptor for TGF-b. However,
in endothelial cells, it has been suggested that ALK-1 may
also function as a type I receptor for TGF-b [58]. In addi-
tion to the type I, II, and III TGF-b receptors, endoglin is
another integral membrane protein that binds TGF-b1 and
TGF-b3, and is highly expressed in endothelial cells [59].
Although TGF-b effects appear to be mediated mostly by
the receptor specific Smad2 and Smad3 proteins [47,48],
there is evidence that Smad5 is involved in TGF-b signal-
ing in hematopoietic cells [60]. Targeted disruption of
genes encoding various components of the TGF-b signal-
ing pathway, including TGF-b1 itself [61], its receptors,
TbRII [62], ALK-1 [63], and endoglin [64], and one of its
signal transducers, Smad5 [65], has each revealed that
these proteins play an important role in vascular develop-
ment. The phenotype of the TGF-b1 and TbRII knockout
mice is virtually indistinguishable and is characterized by
defective endothelial differentiation resulting in abnormal
capillary tube formation [61,62]. In contrast, disruption of
ALK-1, endoglin, or Smad5 does not affect endothelial dif-
ferentiation or vasculogenesis, but instead they each
affect angiogenesis. In addition, endoglin–/– and
Smad5–/–  mice exhibit impaired vascular smooth muscle
cell development. These results are consistent with previ-
ous reports demonstrating that TGF-b can regulate
smooth muscle cell differentiation and migration in vitro
[66•], thus contributing to pericyte recruitment and vessel
stabilization. This hypothesis, as it applies to tumor angio-
genesis, is somewhat challenged by the notion that the
majority of intratumoral neovessels seem to lack perien-
dothelial smooth muscle cells [67], suggesting that there
may be additional roles for the TGF-bs in tumor angiogen-
esis. In that light, Higaki and Shimokado [68] recently
reported TGF-b1-mediated stimulation of phosphatidyli-
nositol-3 kinase activity and amino acid uptake in vascular
smooth muscle cells, suggesting a direct anti-apoptotic
role for TGF-b. Elucidation of the paracrine mechanisms
driving TGF-b-mediated tumor angiogenesis requires
further investigation.
Further supporting the role of TGF-bs in tumor angiogene-
sis, administration of a neutralizing TGF-b1 antibody to
nude mice harboring CHO cell xenografts transfected with
ectopic TGF-b1 inhibits both tumor growth and intratumor
microvessel density [69]. In addition, a monoclonal anti-
body that blocks TGF-b1, TGF-b2, and TGF-b3 has been
shown to suppress the growth of TGF-b1-overexpressing
renal cancer xenografts [70]. In this study, the TGF-b
blocking monoclonal-abrogated factor VIII staining in the
xenografts, suggesting an antitumor mechanism that
targets endothelial cells [70]. Furthermore, TGF-b1 and
PAI-1 have been shown to inhibit the conversion of plas-
minogen to the anti-angiogenic molecule angiostatin in
medium conditioned by human pancreatic cancer cells
[71]. This suggests an additional pro-angiogenic mecha-
nism for TGF-b by interfering with the production of
endogenous inhibitors of endothelial cell proliferation.
Finally, high levels of TGF-b1 mRNA correlate strongly with
high microvessel density in breast tumors, and each of
these factors is associated with poor patient outcome [72].
Host immunosuppression
TGF-b1 and TGF-b2 are potent immunosuppressants
[73]. Thus, elevated levels of TGF-bs secreted by tumors
could potentially inhibit immune effector cells and favor
tumor progression. In support of this idea, Torre Amione et
al [74] demonstrated that, unlike parental tumor cells,
fibrosarcoma cells transfected to express 10ng/ml
TGF-b1 in vitro are unable to induce cytotoxic T lympho-
cyte (CTL) responses and can escape immune recogni-
tion. Likewise, EMT6 mammary tumor cells, which
produce high levels of TGF-b1, can inhibit CTLs in vivo.
Transfection of these cells with interleukin-2, a known
T cell growth factor, can reverse this TGF-b1 effect and
induce tumor rejection [75]. This result suggests that, by
dampening the generation of tumor reactive T cells, TGF-b
can promote tumor viability. There is also evidence that
overexpression of the soluble TbRII extracellular domain in
thymoma cells can prevent the progression of unmodified
thymoma cells when injected near the primary tumor inoc-
ulation site [76], further suggesting that secretion of
soluble TbRII by these cells is sufficient to restore tumor
specific cellular immunity and mediate partial tumor rejec-
tion. Overall, these results are consistent with the pheno-
type of TGF-b1 null mice that die shortly after birth as a
result of widespread inflammation and multiorgan T cell
infiltration and necrosis [77].
In addition to inhibiting CTL responses, TGF-bs can mod-
ulate other immune functions that may favor tumor pro-
gression. For example, CHO cells transfected with an
expression vector encoding latent TGF-b1, when injected
into nude mice, can decrease mouse spleen natural killer
activity and rapidly form tumors [78]. Antagonizing TGF-bs
by intraperitoneal injection of an antibody that neutralizes
TGF-b1, TGF-b2, and TGF-b3 has the opposite effect. It
prevents tumor and metastases formation by MDA-231
human breast carcinoma cells, and markedly increases
natural killer activity of mouse splenocytes [79]. Consis-
tent with this TGF-b-mediated immunosuppressive effect,
reduced immune function has been observed in animals
Breast Cancer Research    Vol 2 No 2 Dumont and Arteagabearing TGF-b overexpressing tumors [80] as well as in
patients with glioblastoma, a common type of brain tumor
that frequently overexpresses TGF-b2 [81].
The cited studies suggest that tumor cell secreted TGF-bs
may block the efferent function of immune effectors at
sites of tumor implantation. Other reports, however,
suggest tumor cell TGF-bs may modify the afferent com-
ponent of the immune response and confer antitumor
immunity. Stable infection of breast and glioma tumor cells
with antisense TGF-b1 and antisense TGF-b2 retro-
viruses, respectively, has been shown to restore the
immunogenicity of these tumor cells when injected into
immunocompetent animals. Furthermore, they induce a
partial rejection of unmodified, less immunogenic estab-
lished wild type tumor cells [82,83]. In both of these
studies, in vitro and in vivo CTL activity was markedly
increased in medium conditioned by antisense TGF-b-
infected cells and/or in mice injected with tumor cells
bearing the antisense compared with tumor cells infected
with a control vector. These studies have therapeutic
implications for the use of an antisense TGF-b based
approach as a means of adoptive immunotherapy against
TGF-b overproducing tumors.
Alternative views and conclusions
A tumor permissive role for the TGF-bs may not apply to
all solid tumors. Indeed, transfection of an antisense
TGF-b1 expression vector into FET and CBS well-differen-
tiated human colon cancer cells has been shown to
enhance tumor formation in nude mice [84,85], supporting
the notion that, in some fully transformed cells, endoge-
nous TGF-b1 can continue to mediate a tumor suppressor
function. In a recent report, mice bearing transplanted gall-
bladder Mz-Cha-2 tumors showed inhibition of angiogene-
sis and leukocyte–endothelial cell interactions at a distant
cranial site and threefold higher levels of circulating
TGF-b1 compared with tumor free mice [86]. This reduc-
tion in microvessel density and leukocyte rolling were
reversed by systemic administration of a TGF-b1 neutraliz-
ing antibody, suggesting a negative role for TGF-b1 in
early neovascularization. Moreover, in a recent survey of
104 in situ and invasive primary breast carcinomas, 40/45
(89%) tumors with low invasive potential and low prolifera-
tion rate exhibited high levels of TbRII by immunohisto-
chemistry [22]. Whether autocrine TGF-b signaling is
causally associated with the observed low proliferation
and invasiveness in this subset of breast tumors is a ques-
tion that remains unclear.
Nonetheless, the potential tumor promoting effects of
TGF-b provide novel molecular targets for interventions
aimed at altering the natural history of solid tumors. The
lack of an obvious physiological role for TGF-b signaling in
postdevelopmental normal physiological states suggests
that these interventions may in fact be tumor specific and
spare the tumor host from undue toxicity. Several
approaches have been proposed, including the use of
blocking antibodies against TGF-b1, TGF-b2, and
TGF-b3, using the soluble ectodomains of the type II
and III TGF-b receptors, which would sequester TGF-b
isoforms at tumor sites and prevent binding to cognate
receptors [87,88], and, finally, using adenovirus encoding
inhibitors of TGF-b signaling [89], to name a few. The
theoretical and logistical strengths and limitations of these
approaches are beyond the scope of this review. Nonethe-
less, these represent tools that, if effective in blocking
TGF-b action, will allow us to address the net effect of
autocrine/paracrine TGF-b signaling at early and late
stages of transformation and cancer progression.
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